An interventional study of NB1 in Degenerative Disc Disease and Spondylolisthesis, sponsored by Bone Biologics Corp. Recruiting at 2 sites in Australia. Open to participants aged 17 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Bone Biologics Corp · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Intervertebral Disc Degeneration with a site in Australia — 4 open to participants now, 5 under way, none of them phase 3. Intervertebral Disc Degeneration · Australia.
Among the 13 studies in Intervertebral Disc Degeneration with a site in Australia, this one is the 10th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2024, is one of 6 with no phase, and was the 8th registered.
462 studies on the registry are indexed under Intervertebral Disc Degeneration; 100 are open to participants now.
Browse Intervertebral Disc Degeneration studies →4 of the 13 studies in Intervertebral Disc Degeneration with a site in Australia are open now. Recruiting first, the newest first:
Zetagen Therapeutics, Inc · Sites in Australia
Ages 22–75 · Healthy volunteers
Locate Bio Pty Ltd · Sites in Australia, United States
Ages 22–80
Cartago Biotech Pty Ltd · Sites in Australia
Ages 18+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 60 Intervertebral Disc Degeneration studies recruiting now, 29 (48%) set no upper age limit and 16 (27%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.
This study: 17 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 1 · Phase 4 1
First in 2006; this study’s year is marked. 3 started in 2024.
This study's planned enrollment of 30 is below the median of 60 across 256 interventional studies indexed under Intervertebral Disc Degeneration.
Median enrollment 60 across the 12 interventional studies, 234 across the 1 observational. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 13 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Bone Biologics Corp as lead sponsor.
Bone Biologics Corp has 1 study filed under Intervertebral Disc Degeneration — fewer than ten, so there is no comparison to draw.
1 of the studies in Intervertebral Disc Degeneration with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03810573Bone Biologics CorpEvaluation of NB1 Bone Graft Following Lumbar Interbody Arthrodesis | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Intervertebral Disc Degeneration with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this clinical study is to evaluate the safety and effectiveness of NB1 Bone Graft in subjects with degenerative disc disease undergoing transforaminal lumbar interbody fusion.
It is estimated that up to 30 participants will be enrolled in approximately 3 clinical sites. During baseline and follow-up assessments, patients will be asked to undergo x-rays and CT scans; adverse events and immunology will be collected, and; participants will be requested to complete participant questionnaires regarding quality of life, pain and function.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
NB1 low dose
Device: NB1
NB1 high dose
Device: NB1
Autograft
rhNELL-1/DBX
Fusion
Defined by an independent (blinded to treatment) radiological assessment as less than five degrees angular vertebral motion, less than three millimeters of translational movement and evidence of bridging bone between the involved vertebral endplates based on x-rays at 12 months after surgery
Time frame: 12 months
Removal, revision, or supplemental fixation
Whether there was removal, revision or supplemental fixation of the graft material that required reoperation at the index level during the follow-up period of the study
Time frame: 12 months
Plan to share: Yes — As requested
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
No publications or documents are linked to this record.
Started Mar 2024 (actual). Primary completion is estimated for Dec 2026, 33 months after the start.
Of 45 industry-sponsored interventional studies with no phase under Intervertebral Disc Degeneration, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 82. This study's planned 33 months is below that.
Counting every sponsor, half of 85 studies reached it within 50 months; a quarter within 27 and three quarters within 72.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Jun 2025 → Dec 2026 and completion Jun 2026 → Dec 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Intervertebral Disc Degeneration →